Magic mushroom compound tested as opioid addiction aid

NCT ID NCT06796062

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder who continue using illicit opioids even while on methadone. Up to 480 participants will receive either a low (1 mg), medium (20 mg), or high (30 mg) dose. The study measures how many weeks they stay free of illicit opioid use over 24 weeks, along with safety and craving changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new way to help people with opioid addiction who haven't been helped by standard treatments alone.
What could go wrong: This is a mid-stage trial with only a single dose of psilocybin. It may not show clear benefits, and side effects like anxiety or changes in heart rhythm are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Duke City Recovery Toolbox
RECRUITING

Albuquerque, New Mexico, 87102, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
StartCare
RECRUITING

Brooklyn, New York, 11206, United States
University of New Mexico
RECRUITING

Albuquerque, New Mexico, 87106, United States
VIP Community Services, Inc
RECRUITING

The Bronx, New York, 10457, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.